CD19 and lymphoma: In a phase I/IIA study of CD19 CAR-T for patients with chemotherapy resistant or refractory CD19+ leukemia and lymphoma, all patients had CRS; severe CRS developed in 27% of the patients and was effectively treated with tocilizumab1.